On the basis of its broad pharmacological activities and our findings, SAB shows potential for use as a therapeutic agent against arecoline-induced oral cancer progression and holds promise for the future development of drugs for use in oral cancer therapy. The gene discussed is SH3BP5; the disease is lip and oral cavity carcinoma.